세계의 염기 활성 뉴클레아제 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Salt Active Nuclease was estimated to be worth US$ 18.22 million in 2024 and is forecast to a readjusted size of US$ 39.09 million by 2031 with a CAGR of 12.1% during the forecast period 2025-2031.

Salt Active Nuclease is a specialized endonuclease enzyme that retains high enzymatic activity in environments with elevated salt concentrations, typically ranging from 0.5 to 1.0 M NaCl or KCl. Unlike traditional nucleases, which lose efficiency under such conditions, Salt Active Nuclease is designed to degrade both DNA and RNA efficiently in high-salt buffers, making it ideal for use in challenging biochemical and biopharmaceutical processes. It exhibits broad substrate specificity, acting on double-stranded DNA, single-stranded DNA, and RNA, while maintaining high stability and activity across a wide pH and temperature range.

This enzyme is widely used in applications such as recombinant protein purification, vaccine production, and gene therapy workflows, where the removal of host cell nucleic acids is critical. Its resistance to denaturing agents and compatibility with downstream processing steps (e.g., chromatography) make it a valuable tool in high-salt environments where traditional nucleases are ineffective. Additionally, Salt Active Nuclease is easily inactivated by heat or chemical treatment, ensuring safe and controllable use in regulated bioprocessing systems.

As a key tool for removing residual nucleic acids in bioprocessing, Salt Active Nuclease has seen a surge in demand in mRNA vaccine production. Short-term demand correction or supply chain adjustment in the post-epidemic era. The subsequent growth rate will resume in 2023-2024, and the market has digested short-term disturbances and returned to a steady expansion track.

From the perspective of production regions, Europe is the largest production region for Salt Active Nuclease, among which production companies represented by ArcticZymes Technologies have a high market share in the world. In terms of revenue, Europe accounted for 49.07% of the global market in 2024 and will continue to maintain its leading position in the future. It is expected that Europe's market share will be 45.51% in 2031.

Europe will continue to dominate high value-added markets (such as GMP-grade enzymes for gene therapy) in the short term thanks to its technological originality (cold-adapted enzyme design), regulatory voice (environmental protection and pharmacopoeia standards) and maturity of the industrial chain.

This report aims to provide a comprehensive presentation of the global market for Salt Active Nuclease, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Salt Active Nuclease by region & country, by Type, and by Application.

The Salt Active Nuclease market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Salt Active Nuclease.

Market Segmentation

By Company

• ArcticZymes Technologies
• Merck
• New England Biolabs
• c-LEcta
• SinoBiological
• ACROBiosystems
• Chaselection

Segment by Type

• R&D Grade
• GMP Grade

Segment by Application

• Recombinant Proteins
• Viral Vaccines
• Viral Vectors
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Salt Active Nuclease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Salt Active Nuclease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Salt Active Nuclease in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Salt Active Nuclease Product Introduction
• 1.2 Global Salt Active Nuclease Market Size Forecast (2020-2031)
• 1.3 Salt Active Nuclease Market Trends & Drivers
  • 1.3.1 Salt Active Nuclease Industry Trends
  • 1.3.2 Salt Active Nuclease Market Drivers & Opportunity
  • 1.3.3 Salt Active Nuclease Market Challenges
  • 1.3.4 Salt Active Nuclease Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Salt Active Nuclease Players Revenue Ranking (2024)
• 2.2 Global Salt Active Nuclease Revenue by Company (2020-2025)
• 2.3 Key Companies Salt Active Nuclease Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Salt Active Nuclease Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Salt Active Nuclease
• 2.6 Salt Active Nuclease Market Competitive Analysis
  • 2.6.1 Salt Active Nuclease Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Salt Active Nuclease Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Salt Active Nuclease as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 R&D Grade
  • 3.1.2 GMP Grade
• 3.2 Global Salt Active Nuclease Sales Value by Type
  • 3.2.1 Global Salt Active Nuclease Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Salt Active Nuclease Sales Value, by Type (2020-2031)
  • 3.2.3 Global Salt Active Nuclease Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Recombinant Proteins
  • 4.1.2 Viral Vaccines
  • 4.1.3 Viral Vectors
  • 4.1.4 Others
• 4.2 Global Salt Active Nuclease Sales Value by Application
  • 4.2.1 Global Salt Active Nuclease Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Salt Active Nuclease Sales Value, by Application (2020-2031)
  • 4.2.3 Global Salt Active Nuclease Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Salt Active Nuclease Sales Value by Region
  • 5.1.1 Global Salt Active Nuclease Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Salt Active Nuclease Sales Value by Region (2020-2025)
  • 5.1.3 Global Salt Active Nuclease Sales Value by Region (2026-2031)
  • 5.1.4 Global Salt Active Nuclease Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Salt Active Nuclease Sales Value, 2020-2031
  • 5.2.2 North America Salt Active Nuclease Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Salt Active Nuclease Sales Value, 2020-2031
  • 5.3.2 Europe Salt Active Nuclease Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Salt Active Nuclease Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Salt Active Nuclease Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Salt Active Nuclease Sales Value, 2020-2031
  • 5.5.2 South America Salt Active Nuclease Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Salt Active Nuclease Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Salt Active Nuclease Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Salt Active Nuclease Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Salt Active Nuclease Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Salt Active Nuclease Sales Value, 2020-2031
  • 6.3.2 United States Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Salt Active Nuclease Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Salt Active Nuclease Sales Value, 2020-2031
  • 6.4.2 Europe Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Salt Active Nuclease Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Salt Active Nuclease Sales Value, 2020-2031
  • 6.5.2 China Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Salt Active Nuclease Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Salt Active Nuclease Sales Value, 2020-2031
  • 6.6.2 Japan Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Salt Active Nuclease Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Salt Active Nuclease Sales Value, 2020-2031
  • 6.7.2 South Korea Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Salt Active Nuclease Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Salt Active Nuclease Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Salt Active Nuclease Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Salt Active Nuclease Sales Value, 2020-2031
  • 6.9.2 India Salt Active Nuclease Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Salt Active Nuclease Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 ArcticZymes Technologies
  • 7.1.1 ArcticZymes Technologies Profile
  • 7.1.2 ArcticZymes Technologies Main Business
  • 7.1.3 ArcticZymes Technologies Salt Active Nuclease Products, Services and Solutions
  • 7.1.4 ArcticZymes Technologies Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.1.5 ArcticZymes Technologies Recent Developments
• 7.2 Merck
  • 7.2.1 Merck Profile
  • 7.2.2 Merck Main Business
  • 7.2.3 Merck Salt Active Nuclease Products, Services and Solutions
  • 7.2.4 Merck Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Merck Recent Developments
• 7.3 New England Biolabs
  • 7.3.1 New England Biolabs Profile
  • 7.3.2 New England Biolabs Main Business
  • 7.3.3 New England Biolabs Salt Active Nuclease Products, Services and Solutions
  • 7.3.4 New England Biolabs Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.3.5 New England Biolabs Recent Developments
• 7.4 c-LEcta
  • 7.4.1 c-LEcta Profile
  • 7.4.2 c-LEcta Main Business
  • 7.4.3 c-LEcta Salt Active Nuclease Products, Services and Solutions
  • 7.4.4 c-LEcta Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.4.5 c-LEcta Recent Developments
• 7.5 SinoBiological
  • 7.5.1 SinoBiological Profile
  • 7.5.2 SinoBiological Main Business
  • 7.5.3 SinoBiological Salt Active Nuclease Products, Services and Solutions
  • 7.5.4 SinoBiological Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.5.5 SinoBiological Recent Developments
• 7.6 ACROBiosystems
  • 7.6.1 ACROBiosystems Profile
  • 7.6.2 ACROBiosystems Main Business
  • 7.6.3 ACROBiosystems Salt Active Nuclease Products, Services and Solutions
  • 7.6.4 ACROBiosystems Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.6.5 ACROBiosystems Recent Developments
• 7.7 Chaselection
  • 7.7.1 Chaselection Profile
  • 7.7.2 Chaselection Main Business
  • 7.7.3 Chaselection Salt Active Nuclease Products, Services and Solutions
  • 7.7.4 Chaselection Salt Active Nuclease Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Chaselection Recent Developments

8 Industry Chain Analysis

• 8.1 Salt Active Nuclease Industrial Chain
• 8.2 Salt Active Nuclease Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Salt Active Nuclease Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Salt Active Nuclease Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer